Ingrezza is the first FDA-approved treatment for tardive dyskinesia, or uncontrolled movements of the face and body. The irreversible movement disorder occurs in 5 to 8 percent of patients taking antipsychotic drugs.
Neurocrine said the drug would be priced competitively. Last year, Neurocrine estimated Ingrezza’s net price at $20,000 to $60,000 annually, depending on dosages, reports Reuters.
The drug company plans to launch Ingrezza — its first commercial product — in May.
More articles on supply chain:
FDA identifies safety issues at Mylan HIV drug facility in India
Supply chain tip of the week: Hospital linens cost more than you think
Survey: 5% of healthcare leaders think Trump will take ‘meaningful’ action on drug prices
